Immune Therapeutics, Inc. filed its 10-K on Apr 10, 2023 for the period ending Dec 31, 2022. In this report its auditor, Turner, Stone & Company, LLP, gave an unqualified opinion expressing doubt that the company can continue as a going concern.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.035 USD | +6.06% | -2.78% | -52.05% |
05-20 | Biostax Corp. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
04-16 | Biostax Corp. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
1st Jan change | Capi. | |
---|---|---|
-52.05% | 2.93M | |
+11.91% | 118B | |
+11.60% | 106B | |
-4.68% | 24.28B | |
-0.82% | 21.96B | |
-10.12% | 18.16B | |
-42.12% | 16.37B | |
-17.47% | 15.56B | |
+2.77% | 13.63B | |
+34.58% | 12.27B |
- Stock Market
- Equities
- BTAX Stock
- News Biostax Corp.
- Immune Therapeutics, Inc. Auditor Raises 'Going Concern' Doubt